These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 2714145

  • 41. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans.
    Näslund E, Bogefors J, Skogar S, Grybäck P, Jacobsson H, Holst JJ, Hellström PM.
    Am J Physiol; 1999 Sep; 277(3):R910-6. PubMed ID: 10484511
    [Abstract] [Full Text] [Related]

  • 42. Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7--36) amide.
    Heller RS, Aponte GW.
    Am J Physiol; 1995 Dec; 269(6 Pt 1):G852-60. PubMed ID: 8572216
    [Abstract] [Full Text] [Related]

  • 43. Effect of glucagon-like peptide-1 on gastric somatostatin and gastrin secretion in the rat.
    Eissele R, Koop H, Arnold R.
    Scand J Gastroenterol; 1990 May; 25(5):449-54. PubMed ID: 1972810
    [Abstract] [Full Text] [Related]

  • 44. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.
    Byrne MM, Gliem K, Wank U, Arnold R, Katschinski M, Polonsky KS, Göke B.
    Diabetes; 1998 Aug; 47(8):1259-65. PubMed ID: 9703326
    [Abstract] [Full Text] [Related]

  • 45. Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas.
    Fehmann HC, Göke R, Göke B, Bächle R, Wagner B, Arnold R.
    Biochim Biophys Acta; 1991 Feb 19; 1091(3):356-63. PubMed ID: 1705823
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W.
    J Clin Endocrinol Metab; 1993 Apr 19; 76(4):912-7. PubMed ID: 8473405
    [Abstract] [Full Text] [Related]

  • 50. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.
    Näslund E, Gutniak M, Skogar S, Rössner S, Hellström PM.
    Am J Clin Nutr; 1998 Sep 19; 68(3):525-30. PubMed ID: 9734726
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.
    Vilsbøll T, Agersø H, Krarup T, Holst JJ.
    J Clin Endocrinol Metab; 2003 Jan 19; 88(1):220-4. PubMed ID: 12519856
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.
    Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ.
    Diabetologia; 1998 Mar 19; 41(3):271-8. PubMed ID: 9541166
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.